Drug intelligence / Profile preview

human normal immunoglobulin (Octapharma)

Development stage
Approved
Lead developer
Octapharma
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Octagam is a sterile, liquid preparation of highly purified human immunoglobulin G (IgG) derived from pooled human plasma. It is a biologic drug administered intravenously and is available in 5% and 10% concentrations. The 5% formulation is primarily indicated for the treatment of primary humoral immunodeficiency (PI), while the 10% formulation is indicated for chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts and for dermatomyositis (DM) in adults. Octagam works through complex immunomodulatory mechanisms, including the blockade of Fc receptors on phagocytic cells, neutralization of circulating autoantibodies, and modulation of inflammatory cytokines and complement pathways. It is manufactured by Octapharma and marketed in the United States by Pfizer.

Brand names
OctagamOctagam 5%Octagam 10%
Other names
Immune Globulin Intravenous (Human)IVIGHuman Normal Immunoglobulin
02

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on human normal immunoglobulin (Octapharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human normal immunoglobulin (Octapharma).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call